Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination
- 31 May 2006
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (4) , 453-458
- https://doi.org/10.1016/j.nucmedbio.2006.02.005
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical OutcomeJournal of Clinical Oncology, 2005
- Dendritic cells as therapeutic vaccines against cancerNature Reviews Immunology, 2005
- Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificityProceedings of the National Academy of Sciences, 2002
- An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cellsHuman Immunology, 1995
- Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assaysMolecular Immunology, 1994
- Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.The Journal of Experimental Medicine, 1994
- A Critical Role for Conserved Residues in the Cleft of HLA-A2 in Presentation of a Nonapeptide to T CellsScience, 1992
- Empty MHC class I molecules come out in the coldNature, 1990